Login to Your Account

Acorda's inhaled levodopa NDA rebuffed with RTF letter

By Michael Fitzhugh
Staff Writer

Tuesday, August 29, 2017

An FDA refuse-to-file letter has derailed Acorda Therapeutics Inc.'s new drug application for Inbrija, an inhaled levodopa candidate for improving motor function in Parkinson's disease patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription